Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Costa LJ, Davies FE, Monohan GP, Kovacsovics TJ, Burwick N, Jakubowiak AJ, Kaufman JL, Hong WJ, Dail M, Salem AH, Yang X, Al Masud A, Munasinghe WP, Ross JA, Bueno OF, Kumar SK, Stadtmauer E..
![top](data:image/svg+xml,%3Csvg%20xmlns="http://www.w3.org/2000/svg"%20width="16"%20height="16"%3E%3Crect%20fill-opacity="0"/%3E%3C/svg%3E "top")
